Skip to main content
Altuviiio logo

ALTUVIIIO® Patient Experiences 


"I always tell my son's care team how happy we are that we switched to ALTUVIIIO.”
 

Prioritizing treatment

Emilio was born in Puerto Rico, where there were few doctors who specialized in hemophilia and there were so many unknowns. So, when Emilio was 4 years old, we moved to the United States. Since then, my relationship with my son's doctor has always been open, and our communication has been clear and in sync at all times. I always leave their office with peace of mind.
 

Setting treatment goals

When Emilio was 7, he started becoming more active and his doctor had him switch from on-demand to prophylaxis, infusing twice a week. Since then, he has made basketball a frequent part of his busy schedule, so it's important to be confident in his bleed protection.
 

Making the switch

My son has been using the same factor for his entire life, so I have always been very hesitant when considering switching. But it was a very smooth and easy transition since the beginning. Our hematologist explained that ALTUVIIIO has been shown to have higher-for-longer factor levels for multiple days of the week, and our HTC nurse was amazing at helping us with any questions we had regarding ALTUVIIIO and insurance.
 

Discovering what’s possible

The impact of ALTUVIIIO in our life was transparent and straightforward. Since starting ALTUVIIIO, Emilio hasn’t had any bleeds. We are confident he is getting the bleed protection he needs, and all this being possible with fewer infusions is a win-win in my book. We are grateful for ALTUVIIIO.

This testimonial reflects one patient’s experience and has not been clinically evaluated. It is not intended to imply typical outcomes or substitute for clinical evidence. Allison is a promotional speaker compensated by Sanofi.

HTC=hemophilia treatment center.  

Discover More Patient Experiences

Indication

ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a von Willebrand Factor (VWF) independent recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with Hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment & control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII are possible following administration of ALTUVIIIO. Neutralizing antibodies were not reported in the clinical trials. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Indication

Important Safety Information

© 2025 Sanofi. All rights reserved. ALTUVIIIO, MyALTUVIIIO, and Sanofi are registered trademarks of Sanofi or an affiliate. MAT-US-2508205-v1.0-11/2025 Last Updated: November 2025